Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
lloyd.king@paediatrics.ox.ac.uk

Lloyd King

Recent publications

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Silk SE. et al, (2024), Lancet Infect Dis, 24, 1105 - 1117

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.

King LDW. et al, (2024), Cell Rep Med, 5

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.

Silk SE. et al, (2023), Med, 4, 668 - 686.e7

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.

Hou MM. et al, (2023), Sci Transl Med, 15

Impact of a blood-stage vaccine on Plasmodium vivax malaria.

Hou MM. et al, (2022)

More publications